Please check your internet connection and try again.
# Clobazam (oral formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is structurally similar to diazepam but possesses a unique 1,5-benzodiazepine ring.
## Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week as tolerated to a target dose of 20 mg twice daily.
* **Maximum:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing (2 years and older)
* **Initiation:** 2.5 mg twice daily.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week as tolerated to a target dose based on weight:
* 10 kg to < 30 kg: 10 mg twice daily (20 mg/day)
* ≥ 30 kg: 20 mg twice daily (40 mg/day)
* **Maximum:** As above, based on weight.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose reduction guidelines are established, but initiation at lower doses and slower titration may be warranted.
* **Renal Impairment:** Use with caution. No specific dose reduction guidelines are established.
* **Concomitant Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole):** May require dose reduction of clobazam.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic impairment.
* Myasthenia gravis.
* Severe sleep apnea.
## Adverse Effects
* **Common:** Drowsiness, somnolence, constipation, decreased appetite, pneumonia, aggression, irritability, difficulty sleeping.
* **Serious:** Suicidal behavior and ideation, respiratory depression, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), dependence and withdrawal symptoms, cognitive impairment, paradoxical reactions.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedating antihistamines):** Additive CNS depressant effects, increased risk of sedation and respiratory depression.
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole):** May increase clobazam plasma concentrations.
* **Strong CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam plasma concentrations.
* **Valproic Acid:** Increased risk of valproic acid-induced toxicity, including hyperammonemia.
* **CNS Stimulants:** May reduce the efficacy of CNS stimulants.
## Monitoring
* **Efficacy:** Assess for reduction in seizure frequency.
* **Adverse Effects:** Monitor for somnolence, behavioral changes, respiratory status, and signs of withdrawal.
* **Suicidal Ideation/Behavior:** Monitor for emergence or worsening of suicidal thoughts and behaviors.
* **Withdrawal Symptoms:** Assess for signs of withdrawal upon discontinuation (e.g., anxiety, insomnia, tremor, nausea).
## Clinical Pearls
* Clobazam is typically initiated at a low dose and slowly titrated to minimize adverse effects, particularly somnolence.
* Patients and caregivers should be advised about the risk of suicidal thoughts and behaviors and the importance of reporting any such changes.
* Abrupt discontinuation should be avoided due to the risk of withdrawal symptoms. Tapering of the dose is recommended.
* The active metabolite, N-desmethylclobazam (norclobazam), also has anticonvulsant activity and a longer half-life.
* Dosing adjustments in pediatric patients may be based on weight tiers; consider more frequent reassessment in rapidly growing children.
***
*Disclaimer: This information is intended for educational purposes and does not substitute for professional medical advice. Always consult the current prescribing information and your healthcare provider for definitive guidance.*
